【摘要】 目的 CT导向下125I放射性粒子植入治疗膈顶部原发性肝癌的可行性、安全性及有效性。方法自2006年1月~2011年10月,共收集46例无法手术切除的膈顶部原发性肝癌患者,共膈顶部病变49个。根据术前强化CT利用TPS计划系统设定125I剂量和分布在CT导向下行125I粒子植入。125I处方剂量(匹配周边剂量):150~200Gy。结果本组46例患者均按计划顺利完成介入治疗。平均植入125I粒子65.6粒。3、6、9、12个月的肿瘤局疗控制率(CR+PR)分别为30.6%、69.4%、55.3%及46.3%(P<0.05)。无严重并发症发生。结论 CT导向介入治疗膈顶部原发性肝癌是一种安全、有效的微创局部治疗手段。更多还原

【Abstract】 Objective To study the feasibility,safety and efficacy of CT-guided 125I seeds implantation for hepatocellular carcinoma(HCC)located in the hepatic dome.Methods A total of 46patients with unresectable HCC comprising 49nodules located in the hepatic dome were treated from January 2006to October 2011.The 125I seeds were implanted according to the TPS program with the preoperative enhanced CT images under the CT-guided.The 125I prescription dose(matched peripheral dose)was 150to 200Gy.Results CT-guided 125I seeds implantation was technically feasible in all the patients.The average implantation of 125I seeds was 65.6.The 3,6,9,12month tumor control rate(CR + PR)was 30.6%,69.4%,55.3%and 46.3%(P <0.05),respectively.No other major complications were observed.Conclusion The CT-guided 125I seeds implantation was a safe and effective minimally invasive local treatment method for hepatocellular carcinoma(HCC)located in the hepatic dome.更多还原